Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Matlashewski

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
NPJ Vaccines|February 14, 2025
LmCen<sup>-/-</sup> based vaccine is protective against canine visceral leishmaniasis following three natural exposures in TunisiaThouraya Boussoffara, Imen Labidi, Malek Trimèche, et al.
Communications Biology|July 31, 2021
Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasisSubir Karmakar, Nevien Ismail, Fabiano Oliveira, et al.
Nature Communications|July 12, 2020
A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editingWen-Wei Zhang, Subir Karmakar, Sreenivas Gannavaram, et al.
Ebiomedicine|April 17, 2026
An observational study to test the potency of GLP-grade phenol-free lyophilised leishmanin antigen formulationThalia Pacheco-Fernandez, Laura Klenow, Shin-Ichi Inoue, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
NPJ Vaccines|February 14, 2025
LmCen<sup>-/-</sup> based vaccine is protective against canine visceral leishmaniasis following three natural exposures in TunisiaThouraya Boussoffara, Imen Labidi, Malek Trimèche, et al.
Communications Biology|July 31, 2021
Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasisSubir Karmakar, Nevien Ismail, Fabiano Oliveira, et al.
Nature Communications|July 12, 2020
A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editingWen-Wei Zhang, Subir Karmakar, Sreenivas Gannavaram, et al.
Ebiomedicine|April 17, 2026
An observational study to test the potency of GLP-grade phenol-free lyophilised leishmanin antigen formulationThalia Pacheco-Fernandez, Laura Klenow, Shin-Ichi Inoue, et al.
Pageof 11